Almac Expands Global Coverage by Adding Depots for Clinical Trial Supply Distribution to the Asia Pacific Region
News Aug 24, 2011
Almac’s Clinical Services business unit, have increased its presence in the Asia Pacific region.
It has extended its reach by adding five new depots located in - Japan, Thailand, Hong Kong, Taiwan to its extensive global depot network.
These latest developments in the Asian market enable Almac to provide customers with even more flexibility in their supply chain solution for their specific country clinical trial requirements. The number of depots within the Network is now 36 with a further 5 planned for 2012.
As part of Almac’s continued expansion of services globally they have also sought to expand their controlled drug network in Europe to ensure they have a network capable of storing this class of drugs within each EU country.
Almac’s Global Depot Network is managed by dedicated depot management teams who serve as the central contact point for the network and also perform regular visits to the depots which are fully audited and GMP compliant.
In line with continuous depot expansion the resources within the Depot Management Team have also increased over the past 6 months. There are now 15 members of staff who are located in the UK, USA and Brazil that are dedicated to managing protocols across the depot network.
Mark Woolf, Global Depot Manager for Almac’s Clinical Services business unit commented ‘The latest depots are a very welcome addition to our network and have been strategically positioned in locations worldwide to ensure we can supply emerging markets with a consistent high level of service.’
Almac has over 20 years experience in the management of clinical trial supplies serving the majority of the top pharma and Biotech companies.
Alongside distribution services Almac also provides specialist packaging/ labelling services, QP & Clinical Supply Management consulting services.
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE